Advertisement


Hope S. Rugo, MD, on Metastatic Breast Cancer: Treatment for Pretreated Hormone Receptor–Positive Disease

2018 San Antonio Breast Cancer Symposium

Advertisement

Hope S. Rugo, MD, of the University of California, San Francisco, discusses how treatment with a lower dose of palbociclib (100 mg vs 125 mg) in combination with fulvestrant or tamoxifen is associated with a lower rate of high-grade neutropenia (Abstract PD2-12).



Related Videos

Breast Cancer

Shom Goel, MD, PhD, on Breast Cancer: Impact of CDK4/6 Inhibitors on Immunity

Shom Goel, MD, PhD, of the Dana-Farber Cancer Institute, discusses preclinical data that suggest CDK4/6 inhibitors not only stop the growth of breast cancer cells, but also enhance...

Breast Cancer
Issues in Oncology

Shoshana M. Rosenberg, ScD, on Quality of Life and the Impact of Breast Cancer Surgery

Shoshana M. Rosenberg, ScD, of Dana-Farber Cancer Institute, discusses her study findings on the lower quality of life associated with mastectomy, and the need for intervention and...

Breast Cancer

Harold J. Burstein, MD, PhD, and Daniel F. Hayes, MD, on Breast Cancer With Positive Lymph Nodes: Treatment Controversy

Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, and Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center debate whether all wom...

Breast Cancer

Xavier Pivot, MD, PhD, on Early Breast Cancer: Results From the PHARE Trial

Xavier Pivot, MD, PhD, of the Paul Strauss Cancer Center, discusses final study findings comparing 6 and 12 months of trastuzumab in adjuvant early breast cancer (Abstract GS2-07)....

Breast Cancer
Genomics/Genetics

Dejan Juric, MD, on Advanced Breast Cancer: Results From the SOLAR-1 Trial

Dejan Juric, MD, of Massachusetts General Hospital, discusses phase III study findings on liquid biopsy–based assessment of PIK3CA mutational status and the combination of...

Advertisement

Advertisement



;
Advertisement